Human TRAIL R2/TNFRSF10B Antibody

Catalog #: AF631
28 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF631
AF631-SP

Detection of Human TRAIL R2/TNFRSF10B by Western Blot.

1 Image

Product Details

Citations (28)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TRAIL R2/TNFRSF10B Antibody Summary

Species Reactivity

Human

Specificity

Detects human TRAIL R2/TNFRSF10B in direct ELISAs and Western blots.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B Ala54-Glu182 Accession # Q6FH58

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

See below

Agonist Activity

Measured by its ability to induce apoptosis on Jurkat human acute T cell leukemia cells. The ED₅₀ for this effect is typically 7.00 - 70.0 ng/mL.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human TRAIL R2/TNFRSF10B by Western Blot. Western blot shows lysates of HepG2 human hepatocellular carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human TRAIL R2/TNFRSF10B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF631) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF019). A specific band was detected for TRAIL R2/TNFRSF10B at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.

Background: TRAIL R2/TNFRSF10B

Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

References

Chaudhary, P.M. et al. (1997) Immunity 7:821.
Walczak, H. et al. (1997) EMBO J. 16:5386.
Golstein, P. (1997) Curr. Biol. 7:R750.

Long Name

TRAIL Receptor 2

Entrez Gene IDs

8795 (Human); 21933 (Mouse)

Alternate Names

CD262 antigen; CD262; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; DR5; DR5TRICK2B; Fas-like protein; KILLER/DR5; KILLERapoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL R2; TRAIL receptor 2; TRAILR2; TRAIL-R2apoptosis inducing receptor TRAIL-R2; TRAILR2cytotoxic TRAIL receptor-2; TRICK2; TRICK2A; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human TRAIL R2/TNFRSF10B Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

28 Citations: Showing 1 - 10
Filter your results:

Filter by:

Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells
Authors: R Yerbes, R Mora-Molin, FJ Fernández-, L Hiraldo, A López-Riva, C Palacios
Cell Death & Disease, 2022-10-27;13(10):906.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
cFLIP downregulation is an early event required for endoplasmic reticulum stress-induced apoptosis in tumor cells
Authors: R Mora-Molin, D Stöhr, M Rehm, A López-Riva
Cell Death & Disease, 2022-02-03;13(2):111.
Species: Human
Sample Types: Cell Lysates, Whole Cells
Applications: Flow Cytometry, Western Blot
Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models
Authors: M Kopczynski, M Statkiewic, M Cybulska, U Kuklinska, K Unrug-Biel, Z Sandowska-, A Grochowska, M Gajewska, M Kulecka, J Ostrowski, M Mikula
International Journal of Molecular Sciences, 2021-03-19;22(6):.
Species: Human
Sample Types: Whole Cells
Applications: ICC
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas
Authors: Y An, J Jeon, L Sun, A Derakhshan, J Chen, S Carlson, H Cheng, C Silvin, X Yang, C Van Waes, Z Chen
Scientific Reports, 2021-03-18;11(1):6392.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
Authors: Y Shlyakhtin, V Pavet, H Gronemeyer
Cell Death Dis, 2017-08-31;8(8):e3025.
Species: Human
Sample Types: Cell Lysates
Applications: Immunoprecipitation
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
Authors: V Liapis, A Zysk, M DeNichilo, I Zinonos, S Hay, V Panagopoul, A Shoubridge, C Difelice, V Ponomarev, W Ingman, GJ Atkins, DM Findlay, ACW Zannettino, A Evdokiou
Cancer Med, 2017-08-10;0(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Authors: Kim, Seong Mu, Woo, Ji Sun, Jeong, Chang Hy, Ryu, Chung He, Jang, Jae-Deog, Jeun, Sin-Soo
Stem Cells Transl Med, 2014-01-16;3(2):172-82.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
Authors: Park SJ, Sohn HY, Yoon J, Park SI
Cell. Signal., 2009-05-24;21(10):1495-503.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Authors: Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH
Biochem. J., 2009-04-28;420(1):73-81.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry, Neutralization
Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Authors: Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH
Biochem. Pharmacol., 2009-01-24;77(8):1328-36.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Authors: Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M
Int. J. Oncol., 2008-08-01;33(2):381-8.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Authors: Wu CH, Kao CH, Safa AR
Hum. Gene Ther., 2008-07-01;19(7):731-43.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization

Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Authors: Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS
Cancer Res., 2008-01-01;68(1):266-75.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Authors: Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
Int. J. Oncol., 2007-12-01;31(6):1391-402.
Species: Human
Sample Types: Cell Lysates, Whole Cells
Applications: Functional Assay, Western Blot

P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Authors: Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
Biochem. Pharmacol., 2006-05-04;72(3):293-307.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization

Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Authors: Lane D, Cote M, Grondin R, Couture MC, Piche A
Mol. Cancer Ther., 2006-03-01;5(3):509-21.
Species: Human
Sample Types: Whole Cells
Applications: Western Blot

Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Authors: Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL
Biochem. Biophys. Res. Commun., 2005-07-22;333(1):42-50.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
Authors: Morel J, Audo R, Hahne M, Combe B
J. Biol. Chem., 2005-01-31;280(16):15709-18.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.
Authors: Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R
J. Exp. Med., 2004-11-15;200(10):1257-66.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Authors: Chopin V, Slomianny C, Hondermarck H, Le Bourhis X
Exp. Cell Res., 2004-08-15;298(2):560-73.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Authors: Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A
J. Biol. Chem., 2003-11-17;279(6):4093-101.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Authors: Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G
J. Leukoc. Biol., 2003-08-01;74(2):223-32.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization

Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Authors: Mouzakiti A, Packham G
Br. J. Haematol., 2003-07-01;122(1):61-9.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Authors: Voelkel-Johnson C
Cancer Biol. Ther., 2003-05-01;2(3):283-90.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization

Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Authors: Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K
Oncogene, 2003-03-20;22(11):1653-62.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Authors: Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
Circ. Res., 2003-03-20;92(7):732-40.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Authors: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
Oncogene, 2002-08-22;21(37):5673-83.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry

Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Authors: Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR
Cell Death Differ., 2002-03-01;9(3):274-86.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry, Functional Assay, Western Blot